Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice

Autor: Kris G Samsom, Luuk J Schipper, Paul Roepman, Linda JW Bosch, Ferry Lalezari, Elisabeth G Klompenhouwer, Adrianus J de Langen, Tineke E Buffart, Immy Riethorst, Lieke Schoenmaker, Daoin Schout, Vincent van der Noort, Jose G van den Berg, Ewart de Bruijn, Jacobus JM van der Hoeven, Hans van Snellenberg, Lizet E van der Kolk, Edwin Cuppen, Emile E Voest, Gerrit A Meijer, Kim Monkhorst

Publikováno v: Journal of Pathology, 258(2), 179-188. John Wiley and Sons Ltd
Samsom, K G, Schipper, L J, Roepman, P, Bosch, L J W, Lalezari, F, Klompenhouwer, E G, de Langen, A J, Buffart, T E, Riethorst, I, Schoenmaker, L, Schout, D, van der Noort, V, van den Berg, J G, de Bruijn, E, van der Hoeven, J J M, van Snellenberg, H, van der Kolk, L E, Cuppen, E, Voest, E E, Meijer, G A & Monkhorst, K 2022, ' Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice ', Journal of Pathology, vol. 258, no. 2, pp. 179-188 . https://doi.org/10.1002/path.5988

The current increase in number and diversity of targeted anticancer agents poses challenges to the logistics and timeliness of molecular diagnostics (MolDx), resulting in underdiagnosis and treatment. Whole-genome sequencing (WGS) may provide a susta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c6dd8cc4558422774c2363cc2462e3
http://www.scopus.com/inward/record.url?scp=85135241312&partnerID=8YFLogxK